SCHEMBL5559436

SCHEMBL5559436

Cc1c(C(C)C(=O)NC(C)(C)C(=O)O)c2cc(O)ccc2n1C(=O)c1cccc(F)c1

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
AKR1C3 P42330 4/20 0.42
AKR1C2 P52895 4/20 0.42
PTGS1 P23219 2/20 0.37
PTGS2 P35354 2/20 0.37
HTT P42858 2/20 0.35
NPC1 O15118 1/20 0.35
RAB9A P51151 1/20 0.35
CYP3A4 P08684 2/20 0.34
HPGD P15428 2/20 0.34
KDM4E B2RXH2 1/20 0.34
CYP1A2 P05177 1/20 0.34
CYP2D6 P10635 1/20 0.34
MAPT P10636 1/20 0.34
CYP2C9 P11712 1/20 0.34
PKM P14618 1/20 0.34
ALOX15 P16050 1/20 0.34
CYP2C19 P33261 1/20 0.34
HSD17B10 Q99714 1/20 0.34
GAA P10253 1/20 0.33
GFER P55789 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5559434 1.00 AKR1C3 (0.42) AKR1C3AKR1C2PTGS1PTGS2HTT
SCHEMBL5560256 0.90 AKR1C3 (0.42) AKR1C3AKR1C2PTGS1PTGS2HTT
SCHEMBL5555602 0.89 PTGS2 (0.43) PTGS1PTGS2CYP2C19ALDH1A1SMN1; SMN2
SCHEMBL5555608 0.89 PTGS2 (0.43) PTGS1PTGS2CYP2C19ALDH1A1SMN1; SMN2
SCHEMBL5559346 0.88 AKR1C3 (0.37) AKR1C3AKR1C2HTTNPC1RAB9A
SCHEMBL5559350 0.88 AKR1C3 (0.37) AKR1C3AKR1C2HTTNPC1RAB9A
SCHEMBL6424252 0.88 PTGS2 (0.42) AKR1C3AKR1C2PTGS1PTGS2
SCHEMBL6424255 0.88 PTGS2 (0.42) AKR1C3AKR1C2PTGS1PTGS2
SCHEMBL5559024 0.86 AKR1C3 (0.41) AKR1C3AKR1C2PTGS1PTGS2CYP3A4
SCHEMBL5799886 0.86 AKR1C3 (0.41) AKR1C3AKR1C2PTGS1PTGS2CYP3A4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1643961-A4 COX-2 AND FAAH INHIBITORS MICROBIA INC (US) 2007-09-12 EP disclosed
EP-1643961-A2 COX-2 AND FAAH INHIBITORS Microbia, Inc. (US) 2006-04-12 EP disclosed
US-20050234244-A1 Synthesis of COX-2 and FAAH inhibitors IRONWOOD PHARMACEUTICALS, INC. 2005-10-20 US disclosed
US-20050032747-A1 COX-2 and FAAH inhibitors POLYMER CONCEPTS TECHNOLOGIES PBY, INC. 2005-02-10 US disclosed
WO-2005002525-A2 COX-2 AND FAAH INHIBITORS MICROBIA, INC. (US) 2005-01-13 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050032747-A1 COX-2 and FAAH inhibitors FAAH2, FAAH, PTGS2 AKR1C3 585/4885AKR1C2 342/4885PTGS1 6/4885
US-20050234244-A1 Synthesis of COX-2 and FAAH inhibitors FAAH2, FAAH, PTGES2 AKR1C3 577/4885AKR1C2 563/4885PTGS1 7/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.